RT Journal Article SR Electronic T1 Mechanism of Interleukin-1- and Tumor Necrosis Factor α-Dependent Regulation of the α1-Antichymotrypsin Gene in Human Astrocytes JF The Journal of Neuroscience JO J. Neurosci. FD Society for Neuroscience SP 7510 OP 7516 DO 10.1523/JNEUROSCI.20-20-07510.2000 VO 20 IS 20 A1 Tomasz Kordula A1 Marcin Bugno A1 Russell E. Rydel A1 James Travis YR 2000 UL http://www.jneurosci.org/content/20/20/7510.abstract AB The expression of α1-antichymotrypsin (ACT) is significantly enhanced in affected brain regions in Alzheimer's disease. This serine proteinase inhibitor specifically colocalizes with filamentous β-amyloid deposits and recently has been shown to influence both formation and destabilization of β-amyloid fibrils. In the brain, ACT is expressed in astrocytes, and interleukin-1 (IL-1), tumor necrosis factor α (TNF), oncostatin M (OSM), and IL-6/soluble IL-6 receptor complexes control synthesis of this inhibitor. Here, we characterize a molecular mechanism responsible for both IL-1 and TNF-induced expression of ACT gene in astrocytes. We identify the 5′ distal IL-1/TNF-responsive enhancer of the ACT gene located 13 kb upstream of the transcription start site. This 413-bp-long enhancer contains three elements, two of which bind nuclear factor kB (NF-kB) and one that binds activating protein 1 (AP-1). All of these elements contribute to the full responsiveness of the ACT gene to both cytokines, as determined by deletion and mutational analysis. The 5′ NF-kB high-affinity binding site and AP-1 element contribute most to the enhancement of gene transcription in response to TNF and IL-1. In addition, we demonstrate that the 5′ untranslated region of the ACT mRNA does not contribute to cytokine-mediated activation. Finally, we find that overexpression of the NF-kB inhibitor (IkB) totally inhibits any activation mediated by the newly identified IL-1/TNF enhancer of the ACT gene.